Status | Study |
RECRUITING |
Study Name: Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2023-07-14 Interventions: Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES.Stimulation will consist of 1 milliamp stimulation, |
ACTIVE_NOT_RECRUITING |
Study Name: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients Condition: Date: 2023-06-05 Interventions: Cladribine tablets (Mavenclad�, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body wei |
RECRUITING |
Study Name: Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2023-02-01 |
RECRUITING |
Study Name: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2022-12-08 |
RECRUITING |
Study Name: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2022-12-08 |
Completed |
Study Name: Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2022-06-16 Interventions: Not Provided |
Recruiting |
Study Name: Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2017-03-16 Interventions: Drug: Ocrelizumab Ocrelizumab will be administered via IV infusion as specified throughout the treatment |
Not yet recruiting |
Study Name: Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2016-04-03 Interventions: Biological: BCD-054 Biological: Avonex |
Completed |
Study Name: Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis Condition: Multiple Sclerosis, Relapsing-remitting Date: 2016-01-22 Interventions: Other: Modified Paleo diet Nine cups of vegetables and some fruits, meat protein including organ meat, a |
Recruiting |
Study Name: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Condition: Multiple Sclerosis, Relapsing-Remitting Date: 2015-12-18 Interventions: Drug: Ocrelizumab Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (6 |